Manuel Mayr


Affiliation: King's College London
Country: UK


  1. Mayr M, Grainger D, Mayr U, Leroyer A, Leseche G, Sidibe A, et al. Proteomics, metabolomics, and immunomics on microparticles derived from human atherosclerotic plaques. Circ Cardiovasc Genet. 2009;2:379-88 pubmed publisher
  2. Fava M, Barallobre Barreiro J, Mayr U, Lu R, Didangelos A, Baig F, et al. Role of ADAMTS-5 in Aortic Dilatation and Extracellular Matrix Remodeling. Arterioscler Thromb Vasc Biol. 2018;38:1537-1548 pubmed publisher
    ..ADAMTS-5 rather than ADAMTS-1 is the key protease for versican regulation in murine aortas. Further studies are needed to define the ECM substrates of the different ADAMTS proteases and their contribution to TAA formation. ..
  3. Mayr M, Yusuf S, Weir G, Chung Y, Mayr U, Yin X, et al. Combined metabolomic and proteomic analysis of human atrial fibrillation. J Am Coll Cardiol. 2008;51:585-94 pubmed publisher
  4. Kaudewitz D, Zampetaki A, Mayr M. MicroRNA Biomarkers for Coronary Artery Disease?. Curr Atheroscler Rep. 2015;17:70 pubmed publisher
    ..As these limitations have not been previously recognised, a reevaluation of the current miRNA literature, in particular of case-control studies in patients with cardiovascular disease or coronary interventions, is required. ..
  5. Willeit P, Skroblin P, Kiechl S, Fernandez Hernando C, Mayr M. Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?. Eur Heart J. 2016;37:3260-3266 pubmed
    ..This miRNA may therefore constitute a novel biomarker for cardiovascular and metabolic diseases. ..
  6. Pechlaner R, Tsimikas S, Yin X, Willeit P, Baig F, Santer P, et al. Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III. J Am Coll Cardiol. 2017;69:789-800 pubmed publisher
    ..73). The strong associations of VLDL-associated apolipoproteins with incident CVD in the general community support the concept of targeting triacylglycerol-rich lipoproteins to reduce risk of CVD. ..
  7. Barallobre Barreiro J, Gupta S, Zoccarato A, Kitazume Taneike R, Fava M, Yin X, et al. Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in Human Atrial Fibrillation. Circulation. 2016;134:817-32 pubmed publisher
    ..Novel processed forms of decorin protein core, uncovered in human atrial appendages, can regulate the local bioavailability of antihypertrophic and profibrotic growth factors. ..
  8. Barallobre Barreiro J, Oklu R, Lynch M, Fava M, Baig F, Yin X, et al. Extracellular matrix remodelling in response to venous hypertension: proteomics of human varicose veins. Cardiovasc Res. 2016;110:419-30 pubmed publisher
    ..The present proteomics study provides unprecedented insights into the expression and degradation of structural and regulatory components of the vascular extracellular matrix in varicosis. ..
  9. Lynch M, Barallobre Barreiro J, Jahangiri M, Mayr M. Vascular proteomics in metabolic and cardiovascular diseases. J Intern Med. 2016;280:325-38 pubmed publisher
    ..Then, we will describe the challenges associated with studying the intricate network of ECM proteins and the current proteomic strategies to analyse the vascular ECM in metabolic and cardiovascular diseases. ..

More Information


  1. Barallobre Barreiro J, Lynch M, Yin X, Mayr M. Systems biology-opportunities and challenges: the application of proteomics to study the cardiovascular extracellular matrix. Cardiovasc Res. 2016;112:626-636 pubmed
  2. Barwari T, Joshi A, Mayr M. MicroRNAs in Cardiovascular Disease. J Am Coll Cardiol. 2016;68:2577-2584 pubmed publisher
    ..The development of more targeted interventions will bolster well-informed clinical applications, increasing the chances of success and minimizing the risk of setbacks for miRNA-based therapeutics. ..
  3. Sunderland N, Skroblin P, Barwari T, Huntley R, Lu R, Joshi A, et al. MicroRNA Biomarkers and Platelet Reactivity: The Clot Thickens. Circ Res. 2017;120:418-435 pubmed publisher
    ..We provide recommendations for future miRNA biomarker studies, emphasizing the need for accurate interpretation within a biological and methodological context. ..
  4. Gomes R, Skroblin P, Munster A, Tomlins H, Langley S, Zampetaki A, et al. "Young at heart": Regenerative potential linked to immature cardiac phenotypes. J Mol Cell Cardiol. 2016;92:105-8 pubmed publisher
    ..The immature myofilament composition of the fish heart may explain why adult mouse and human cardiomyocytes lack this endogenous repair mechanism. ..
  5. Hinterwirth H, Stegemann C, Mayr M. Lipidomics: quest for molecular lipid biomarkers in cardiovascular disease. Circ Cardiovasc Genet. 2014;7:941-54 pubmed publisher
    ..An in-depth knowledge about the molecular lipid species that contribute to the pathophysiology of cardiovascular diseases may provide better biomarkers and novel therapeutic targets for cardiovascular disease. ..
  6. Barallobre Barreiro J, Baig F, Fava M, Yin X, Mayr M. Glycoproteomics of the Extracellular Matrix: A Method for Intact Glycopeptide Analysis Using Mass Spectrometry. J Vis Exp. 2017;: pubmed publisher
    ..In the present paper, we describe a method to prepare the ECM from tissue samples. The method not only allows for protein profiling but also the assessment and characterization of glycosylation by MS analysis. ..
  7. Suna G, Wojakowski W, Lynch M, Barallobre Barreiro J, Yin X, Mayr U, et al. Extracellular Matrix Proteomics Reveals Interplay of Aggrecan and Aggrecanases in Vascular Remodeling of Stented Coronary Arteries. Circulation. 2018;137:166-183 pubmed publisher
    ..The accumulation of aggrecan coincided with a shift in ADAMTS gene expression. This study provides the first evidence implicating aggrecan and aggrecanases in the vascular injury response after stenting. ..
  8. Mayr M, Liem D, Zhang J, Li X, Avliyakulov N, Yang J, et al. Proteomic and metabolomic analysis of cardioprotection: Interplay between protein kinase C epsilon and delta in regulating glucose metabolism of murine hearts. J Mol Cell Cardiol. 2009;46:268-77 pubmed publisher
    ..Taken together, our findings are the first evidence that PKCvarepsilon activity modulates cardiac glucose metabolism and provide a possible explanation for the synergistic effect of PKCdelta and PKCvarepsilon in cardioprotection. ..
  9. Yin X, Baig F, Haudebourg E, Blankley R, Gandhi T, Müller S, et al. Plasma Proteomics for Epidemiology: Increasing Throughput With Standard-Flow Rates. Circ Cardiovasc Genet. 2017;10: pubmed publisher
  10. Kaudewitz D, Lee R, Willeit P, McGregor R, Markus H, Kiechl S, et al. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thromb Haemost. 2013;110:609-15 pubmed publisher
    ..This has to be taken into account when designing studies to investigate the relation of circulating microRNAs to acute cardiovascular events or coronary intervention. ..
  11. Zervou S, Yin X, Nabeebaccus A, O Brien B, Cross R, McAndrew D, et al. Proteomic and metabolomic changes driven by elevating myocardial creatine suggest novel metabolic feedback mechanisms. Amino Acids. 2016;48:1969-81 pubmed publisher
    ..0002). These findings suggest wide-ranging and hitherto unexpected adaptations in substrate utilisation and energy metabolism with a general pattern of impaired energy generating pathways in mice with very high creatine levels. ..